Evidence map›Paper›PMID 41183079›Full record

ArticlePloS one2025

Research to evaluate safety and impact of long COVID intervention with Ensitrelvir for National Cohort (RESILIENCE Study): A protocol for a randomized, double-blind, placebo-controlled trial.

Keiji Konishi, Shungo Yamamoto, Ryuichi Minoda Sada, Kento Asano, Daisuke Onozuka, Shintaro Tanaka, Shogo Miyazawa, Masahiro Kinoshita, Satoshi Kutsuna

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Keiji KonishiDepartment of Post-infectious disease Therapeutics, Graduate School of Medicine, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0000-0002-1705-6487
Shungo YamamotoDepartment of Infection Control and Prevention, Graduate School of Medicine, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0000-0003-3207-8403
Ryuichi Minoda SadaDepartment of Infection Control and Prevention, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Kento AsanoAcademic Clinical Research Center, Department of Medical Innovation, The University of Osaka Hospital, Osaka, Japan.ORCID https://orcid.org/0009-0000-3191-3484
Daisuke OnozukaDepartment of Post-infectious disease Therapeutics, Graduate School of Medicine, The University of Osaka, Osaka, Japan.ORCID https://orcid.org/0000-0001-9596-9188
Shintaro TanakaMedical Affairs Department, Shionogi and Co., Ltd., Tokyo, Japan.
Shogo MiyazawaData Science Department, Shionogi and Co., Ltd., Osaka, Japan.
Masahiro KinoshitaMedical Affairs Department, Shionogi and Co., Ltd., Osaka, Japan.
Satoshi KutsunaDepartment of Post-infectious disease Therapeutics, Graduate School of Medicine, The University of Osaka, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

trial registrationThis study was registered with the Japan Registry of Clinical Trials on February 16, 2024 (jRCTs051230184, https://jrct.mhlw.go.jp/en-latest-detail/jRCTs051230184).

Indexed as

COVID-19COVID-19 Drug TreatmentCohort StudiesDouble-Blind MethodHumansIndazolesJapanRandomized Controlled Trials as TopicRegistriesSARS-CoV-2TriazinesTriazolesensitrelvirIndazolesTriazinesTriazoles

Identifiers

PMID41183079
PMCPMC12582476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.